Market reaction
Shares of Nuvectis Pharma Inc (NASDAQ:NVCT) rose 5.7% in premarket trading Monday following the company’s announcement of a licensing agreement with Haisco Pharmaceutical Group for exclusive rights to two clinical-stage compounds outside China. The deal is positioned to expand Nuvectis’ clinical-stage footprint and move the company further into late-stage development activities.
The assets added to the pipeline
The agreement transfers two compounds into Nuvectis’ pipeline. NXP100 is a Complement Factor B inhibitor formulated as a once-daily oral therapy. According to the announcement, NXP100 currently has two Marketing Authorization Applications under review in China for Paroxysmal Nocturnal Hemoglobinuria (PNH), and is in Phase 3 development for Immunoglobulin A Nephropathy as well as Phase 2 development for Lupus Nephritis.
Data cited for NXP100 from a Phase 3 PNH study indicate that 59.5% of treatment-naive patients achieved hemoglobin levels of at least 12 g/dL without transfusions, compared with 8.3% for eculizumab in the same analysis. A separate Phase 3 study referenced in the announcement showed that 52.8% of patients who had failed C5 inhibitor treatment reached the same hemoglobin endpoint.
NXP200 is described as an oral, brain-penetrant BRAF inhibitor intended to address limitations associated with first-generation BRAF drugs. The compound has produced single-agent responses across several tumor types, including central nervous system malignancies, colorectal cancer, melanoma, and non-small-cell lung cancer. NXP200 is currently being evaluated in a Phase 1b study in China.
Deal economics and conditions
Under the terms disclosed by the companies, Haisco will receive upfront and near-term payments to Nuvectis totaling up to $40 million. In addition, the deal provides for potential development, regulatory, and commercial milestone payments of up to $1.421 billion, along with tiered royalties on any future sales of the compounds. The licensing arrangement is contingent upon Nuvectis meeting certain financing conditions.
Company comment
In remarks included with the announcement, Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, said that NXP100 has potential to be an effective therapy across multiple complement-mediated diseases and highlighted the convenience of a once-daily oral dosing profile as a potential advantage.
What this means for the company
The transaction expands Nuvectis’ therapeutic scope into complement-mediated disorders and strengthens its oncology assets, positioning the company as a later-stage clinical developer. The agreement also creates a pathway for potential near-term and long-term payments tied to development milestones, regulatory approvals, and commercial performance, while leaving the completion of the transaction subject to Nuvectis satisfying financing requirements.
Note: The transaction details, clinical endpoints, trial phases, and payment figures are presented as disclosed by the companies and reflect information provided at the time of the announcement.